Peptide·plain sequence-like

ATLPC0015432

ECG

Routes

Compare in workbench Download release API JSON

Length
3 aa
Monoisotopic mass
307.1 Da
Net charge @ pH 7.4
-1.00
Isoelectric point
3.85
GRAVY
-0.467

Coveragecounts only · not riskATLPC0015432

Measurements
15
Endpoints
8
Domains
3/5
Products
—

No matrix stability evidence
2 clearance measurements
No immunogenicity context
2 liability motifs

Jump to domain

Open the matching evidence section below

All evidence index · 15

Exposure / Absorption

10 measurements

Distribution / Barrier

3 measurements

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

2 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 3
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0016923	—	—	—	Notation only	—

Residue view

Residue display

3 residues

E1C2G3

Secondary structureα-helix (H)β-strand (E)coil (C)

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

ECG

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references1 reference

3D coordinates·PEPstrMOD predictionpredicted

PEPstrMOD prediction·reference selected·length 3 aa·confidence predicted

Link	Method	Confidence	Match
Open	PEPstrMOD model	predicted	3 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors3 aa · pI 3.9 · GRAVY -0.47

Length: 3 aa
Monoisotopic mass: 307.08 Da
Average mass: 307.32 Da
Net charge at pH 7.4: -1.00
Estimated pI: 3.85
GRAVY: -0.467
KD-positive residues: 33.3%
Aromatic residues: 0.0%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 1.47
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

0.97

pH 5

-0.85

pH 6

-0.99

pH 7.4

-1.13

pH 9

-2.47

pH 12

-3.00

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

1 · 33.3%

Conformational / sulfur (G,P,C)

2 · 66.7%

Top residues

C133.3%E133.3%G133.3%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

1-3

ECG

GRAVY -0.467

Most hydrophilic window

1-3

ECG

GRAVY -0.467

1 local hydropathy window scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

C · pos 2

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Pro/Gly-rich sequence

P/G · pos 3

High Pro/Gly content can affect local flexibility and secondary-structure propensity.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

0.00

Instability index

153.1

Above 40 — predicted unstable in vitro.

Boman index

1.53 kcal/mol

Molar extinction coefficient (280 nm)

0 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 0.00

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Exposure / Absorption

10 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBioavailability AUC Cmax Tmax

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.	Interpret as reported	Not specified	Result: Qualitative or narrative result · Molecular form: not reported · Route: ORAL · 66 · Glutathione · exact product name match · exact or normalized match · Source: Primary reference linked	Source record

AUC3 records · 3 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	1287.5 μg*h/mL	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference
2	645.5 μg*h/mL	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference
3	517.8 μg*h/mL	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference

Cmax3 records · 3 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	103.9 μg/mL	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference
2	45.5 μg/mL	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference
3	42.8 μg/mL	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference

Tmax3 records · 3 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	13.6 h 48960 seconds	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference
2	15.8 h 56880 seconds	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference
3	9.9 h 35640 seconds	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood	Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked	Reference

Distribution / Barrier

3 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBBB penetration Vd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0.152 L/kg	Eligible when experimental context matches	HPLC measurement of GSH/GSSG/total GSH; log-linear trapezoidal PK analysis; Table 2 manual extraction · human · plasma/serum	Result: Reported point value · Molecular form: not reported · Route: intravenous infusion · Dose/window: 0-60 min after baseline subtraction · Time: 0-60 min post-dose PK parameter calculation · Source: Primary reference linked	Reference

BBB penetration2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	22.6 %	Eligible when experimental context matches	Intracarotid injection · blood-brain barrier	Result: Reported point value · Molecular form: not reported · BUI · Saturable · Source: Primary reference linked	Reference
2	22.6 %	Interpret as reported	NA · NA · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Route: Intracarotid injection · Permeability · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

2 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life Clearance

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	9.8 mL/min/kg	Eligible when experimental context matches	HPLC measurement of GSH/GSSG/total GSH; log-linear trapezoidal PK analysis; Table 2 manual extraction · human · plasma/serum	Result: Reported point value · Molecular form: not reported · Route: intravenous infusion · Dose/window: 0-60 min after baseline subtraction · Time: 0-60 min post-dose PK parameter calculation · Source: Primary reference linked	Reference

Half Life1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	apparent plasma total glutathione half life: 1.6 minutes 96 seconds	Eligible when experimental context matches	Not specified	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference

Evidence landscape

15 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

10 evidence records

Distribution / Barrier

3 evidence records

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

2 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Area Under Curve

Max Concentration

Time To Max Concentration

Blood Brain Barrier Penetration

Bioavailability

Clearance

Half Life

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceMatrixRoute

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Half Life	1.6 minutes 96 seconds Result metric: APPARENT_PLASMA_TOTAL_GLUTATHIONE_HALF_LIFE	Reported point value	Eligible when experimental context matches	Not specified	Not specified	Reference Primary reference linked
2	Exposure / Absorption Exposure	Bioavailability	Observation Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.	Qualitative or narrative result	Interpret as reported	Not specified	Route: ORAL	Source record Primary reference linked
3	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	22.6 %	Reported point value	Interpret as reported	NA · blood-brain barrier	Route: Intracarotid injection	Reference Primary reference linked
4	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	22.6 %	Reported point value	Eligible when experimental context matches	Intracarotid injection · blood-brain barrier	Not specified	Reference Primary reference linked
5	Exposure / Absorption Exposure	Area Under Curve	1,287.5 μg*h/mL	Reported point value	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 man...	Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Human randomized crossover supplement PK study. Table 3 reports actual administered-dose, baseline-adjusted whole-b...	Reference Primary reference linked
6	Exposure / Absorption Exposure	Max Concentration	103.9 μg/mL	Reported point value	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 man...	Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Human randomized crossover supplement PK study. Table 3 reports actual administered-dose, baseline-adjusted whole-b...	Reference Primary reference linked
7	Exposure / Absorption Exposure	Time To Max Concentration	13.6 h 48,960 seconds	Reported point value	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 man...	Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Human randomized crossover supplement PK study. Table 3 reports actual administered-dose, baseline-adjusted whole-b...	Reference Primary reference linked
8	Exposure / Absorption Exposure	Area Under Curve	645.5 μg*h/mL	Reported point value	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 man...	Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Human randomized crossover supplement PK study. Table 3 reports actual administered-dose, baseline-adjusted whole-b...	Reference Primary reference linked
9	Exposure / Absorption Exposure	Max Concentration	45.5 μg/mL	Reported point value	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 man...	Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Human randomized crossover supplement PK study. Table 3 reports actual administered-dose, baseline-adjusted whole-b...	Reference Primary reference linked
10	Exposure / Absorption Exposure	Time To Max Concentration	15.8 h 56,880 seconds	Reported point value	Eligible when experimental context matches	LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 man...	Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Human randomized crossover supplement PK study. Table 3 reports actual administered-dose, baseline-adjusted whole-b...	Reference Primary reference linked

1–10 / 15

Identity & reference map

15 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary5 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 5
Measurements: 15
ATL peptide ID: ATLPC0015432

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 15

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 15

Different notation

Reported notation does not resolve to the current display sequence.

1 / 15

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

14 / 15

Reported sequence notation

Different1 reference

gGlu-CG

Current identity

ECG

Reported names

No distinct human-readable aliases are exposed.

Reference map5 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Exposure Area Under Curve, Max Concentration, Time To Max Concentration	No reported alias	9 identity 9 evidence
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	2 identity 2 evidence
Reference Open	DistributionPersistence Clearance, Volume Of Distribution	No reported alias	2 identity 2 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Source record Open	Exposure Bioavailability	No reported alias gGlu-CGdifferent	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0015432
Identity type: canonical sequence
ADMET endpoints: 8
Evidence records: 15
Reference groups: 5
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0015432

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0015432' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0016923

—

Notation only

—

Link

Method

Confidence

Match

Open

PEPstrMOD model

predicted

3 aa

Value

Analysis use

Assay / model

Result context

Reference

Observation

Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.

Interpret as reported

Not specified

Result: Qualitative or narrative result · Molecular form: not reported · Route: ORAL · 66 · Glutathione · exact product name match · exact or normalized match · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

1287.5 μg*h/mL

Eligible when experimental context matches

LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood

Result: Reported point value · Molecular form: not reported · Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling · Source: Primary reference linked